This is a preprint.
Protection against N. gonorrhoeae induced by OMV-based Meningococcal Vaccines are associated with cross-species directed humoral and cellular immune responses
- PMID: 39651121
- PMCID: PMC11623675
- DOI: 10.1101/2024.11.29.626107
Protection against N. gonorrhoeae induced by OMV-based Meningococcal Vaccines are associated with cross-species directed humoral and cellular immune responses
Update in
-
Protection against N. gonorrhoeae induced by OMV-based meningococcal vaccines are associated with cross-species directed humoral and cellular immune responses.Front Immunol. 2025 Apr 11;16:1539795. doi: 10.3389/fimmu.2025.1539795. eCollection 2025. Front Immunol. 2025. PMID: 40292302 Free PMC article.
Abstract
Limited protective immunologic responses to natural N. gonorrhoeae infection and a lack of knowledge about mechanisms of protection have hampered development of an effective vaccine. Recent studies in humans and mice have found meningococcal outer membrane vesicle-containing vaccines (OMV) induce cross species immune responses against gonococci and are associated with protection. The exact mechanisms or how humoral and cellular immunity are related to protection, remain unclear. To study this, we immunized mice with two meningococcal OMV-containing vaccines known to accelerate clearance of N. gonorrhoeae , 4CMenB and OMV from an engineered N. meningitidis strain lacking major surface antigens PorA, PorB, and Rmp (MC58 ΔABR). We assessed serologic and cellular immune signatures associated with these immunizations and assessed bacterial clearance in the mice using a vaginal/cervical gonococcal infection model. Mice immunized with 4CMenB or MC58 ΔABR demonstrated shortened courses of recovery of vaginal N. gonorrhoeae compared to control mice immunized with alum alone. Vaccination with 4CMenB or MC58ΔABR OMV elicited serum and vaginal cross-reactive anti-Ng-OMV antibody responses that were augmented after vaginal challenge with N. gonorrhoeae . Further, splenocytes in 4CMenB and MC58 ΔABR immunized mice exhibited elevated cytokine production after restimulation with heterologous N. gonorrhoeae OMV when compared to splenocytes from Alum immunized mice. We further tested for correlations between bacterial burden and the measured anti-gonococcal immune responses within each vaccination group and found different immunologic parameters associated with reduced bacterial burden for each vaccine. Our findings suggest the cross-protection against gonococcal infection induced by different meningococcal OMV vaccines is likely multifactorial and mediated by different humoral and cellular immune responses induced by these two vaccines.
Similar articles
-
Protection against N. gonorrhoeae induced by OMV-based meningococcal vaccines are associated with cross-species directed humoral and cellular immune responses.Front Immunol. 2025 Apr 11;16:1539795. doi: 10.3389/fimmu.2025.1539795. eCollection 2025. Front Immunol. 2025. PMID: 40292302 Free PMC article.
-
The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.PLoS Pathog. 2020 Dec 8;16(12):e1008602. doi: 10.1371/journal.ppat.1008602. eCollection 2020 Dec. PLoS Pathog. 2020. PMID: 33290434 Free PMC article.
-
Meningococcal vaccine 4CMenB elicits a robust cellular immune response that targets but is not consistently protective against Neisseria gonorrhoeae during murine vaginal infection.mSphere. 2025 May 27;10(5):e0094024. doi: 10.1128/msphere.00940-24. Epub 2025 Apr 16. mSphere. 2025. PMID: 40237483 Free PMC article.
-
Evaluating cross-protection: Meningococcal vaccines show effectiveness in gonorrhoea prevention - A systematic review and meta-analysis.Vaccine. 2025 May 22;56:127188. doi: 10.1016/j.vaccine.2025.127188. Epub 2025 May 6. Vaccine. 2025. PMID: 40334533
-
Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines.Front Immunol. 2019 Apr 9;10:683. doi: 10.3389/fimmu.2019.00683. eCollection 2019. Front Immunol. 2019. PMID: 31024540 Free PMC article. Review.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources